top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

M&As announced YTD in 2024

M&A highlights from last week‚ĶūüĎá




YTD Summary:

Number Announced:      28

Q1 2024 # Announced:  18

Q2 2024 # Announced:  10


Mariana Oncology  

Acquired By: Novartis

Announcement Date: May 2, 2024

Acquisition Price: $1B upfront + up to $750M milestone payment

Acquisition Date (Closed): Pending

Lead Asset: MC-339 

Lead Asset Stage: Preclinical

Indication: Small Cell Lung Cancers


Epygenix Therapeutics  

Acquired By: Harmony Biosciences

Announcement Date: April 30, 2024

Acquisition Price: $35M upfront + up to $130M milestone payment

Acquisition Date (Closed): Pending

Lead Asset: EPX-100 

Lead Asset Stage: Phase 2

Lead Asset Indication: Dravet Syndrome


Deciphera Pharmaceuticals  

Acquired By: ONO Pharmaceuticals

Announcement Date: April 29, 2024

Acquisition Price: $2.4B

Acquisition Date (Closed): Pending

Lead Asset: Ripretinib 

Lead Asset Stage: Approved

Lead Asset Indication: Gastrointestinal stromal tumor



---


Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more




Article History:

RF, DV, DG (05/03/24)


This article is not investment or legal advice.


Comments


bottom of page